Aspen Neuroscience Wins FDA RMAT Designation for ANPD001
SAN DIEGO, July 30, 2026 Aspen Neuroscience, Inc. has received Regenerative Medicine Advanced Therapy (RMAT) designation from the U.S....
dopaminergic neurons
Advertisement
Aspen Neuroscience Completes Cohort 4 in ASPIRO Parkinson’s Trial
SAN DIEGO, June 30, 2026 Aspen Neuroscience, Inc. has announced the successful completion of Cohort 3 and Cohort 4...
TreeFrog’s TFG-001 Shows Strong Parkinson’s Recovery Data
BORDEAUX, France, May 25, 2026 TreeFrog Therapeutics announced new preclinical data showing that its investigational 3D neural microtissue cell...
XellSmart Advances Phase 2 Parkinson’s Cell Therapy Trial
Suzhou, China | April 14, 2026 XellSmart has announced the initiation of a multicenter Phase II clinical trial evaluating...
Advertisement
